Toxic liver injuries;Toxische leberschäden

Therapeutische Umschau

Volumn 61, Issue 8, 2004, Pages 529-534

  Krahenbuhl St ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANTIRHEUMATIC AGENT; AZATHIOPRINE; DICLOFENAC; DIHYDRALAZINE; ERYTHROMYCIN; ESTROGEN; HALOTHANE; ISONIAZID; METHOTREXATE; PARACETAMOL; PENICILLIN G; STEROID; SULFONAMIDE; SULINDAC; VALPROIC ACID;

CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; GERMANY; HISTOPATHOLOGY; HUMAN; LIVER TOXICITY; MEDICAL LITERATURE; MOLECULAR MECHANICS; REVIEW; RISK FACTOR;

EID: 4344670081     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.61.8.529     Document Type: Review

References (28)

1. Zimmerman HJ. Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. Lippincott Williams & Wilkins: Philadelphia, Baltimore, New York, London. 2. edition. 1999.
2. Kaplowitz N, DeLeve LD. Drug-induced liver disease. Marcel Dekker: New York, Basel. 2003.
3. Dossing M, Sonne J. Drug-induced hepatic disorders. Incidence, management and avoidance. Drug Saf 1994; 9: 441-449.
4. Hoofnagle JH, Carithers RL, Jr, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. Hepatology 1995; 21: 240-252.
5. Halls H, Gram LF, Grodum E, Damsbo N, Brosen N. Drug-related admissions to medical wards: a population survey. Br J Clin Pharmacol 1992; 33: 61-68.
6. Bjorneboe M, Iversen O, Olsen S. Infective hepatitis and toxic jaundice in a municipal hospital during a five-year period. Incidence and prognosis. Acta Med. Scand 1967; 182:491-501.
7. Benhamou JP. Drug-induced hepatitis: clinical aspects. In: Fillastre JP, ed. Hepatotoxicity of drugs. University de Rouen: Rouen. 1986: 23-30.
8. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-54.
9. Schiodt FV, Atillasoy E, Shakil AO, et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg 1999; 5: 29-34.
10. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11:272-276.
11. Pessayre D. Role or reactive metabolites in drug-induced hepatitis. J Hepatol 1995; 23 (Suppl. 1): 16-24.
12. Van Pelt FNAM, Straub P, Manns MP. Molecular basis of drug-induced immunological liver injury. Sem Liv Dis 1995;15:283-300.
13. Dahlin DC, Miwa GT, Lu AY, Nelson SD. N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc Natl Acad Sci USA 1984; 81:1327-1331.
14. Kronenberg A, Krahenbuhl S, Zimmermann A, Streuli R. Severe hepatocellular damage after administration of paracetamol and chlorzoxazone in therapeutic dosage. Schweiz Rundsch Med Prax. 1998; 87: 1356-1360.
15. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995; 22: 767-773.
16. Slattery JT, Nelson SD, Thummel KE. The complex interaction between ethanol and acetaminophen. Clin Pharmacol Ther 1996; 60: 241-246.
17. Bonkovsky HL, Kane RE, Jones DP, Galinsky RE, Banner B. Acute hepatic and renal toxicity from low doses of acetaminophen in the absence of alcohol abuse or malnutrition: evidence for increased susceptibility to drug toxicity due to cardiopulmonary and renal insufficiency. Hepatology 1994; 19: 1141-1148.
18. De Morais SM, Uetrecht JP, Wells PG. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. Gastroenterology 1992; 102: 577-586.
19. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994; 272:1845-1850.
20. Krahenbuhl S, Mang G, Kupferschmidt H, Meier PJ, Krause M. Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity. Gut 1995; 37: 140-143.
21. Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995; 67 (1): 101-154.
22. Turnbull DM, Dick DJ, Wilson L, Sherratt HS, Alberti KG. Valproate causes metabolic disturbance in normal man. J Neurol Neurosurg Psychiatry 1986; 49: 405-410.
23. Luder AS, Parks JK, Frerman F, Parker WD Jr. Inactivation of beef brain alpha-ketoglutarate dehydrogenase complex by valproic acid and valproic acid metabolites. Possible mechanism of anticonvulsant and toxic actions. J Clin Invest 1990; 86: 1574-1581.
24. Krahenbuhl S, Brandner S, Kleinle S, Liechti S, Straumann D. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 2000; 20: 346-348.
25. Degott C, Feldmann G, Larrey D, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992; 15: 244-251.
26. Krahenbuhl S., Kaplowitz N. (1996). Drug-induced hepatotoxicity: clinical presentation, pathogenesis, risk factors, diagnosis and treatment. In: Schmid R., Bianchi L., Blum H.E., Gerok W., Maier K.P., Stalder G.A. Acute and chronic liver disease. Molecular biology and clinics. Kluwer Academic Publishers, Dordrecht, Boston, London. 147-158.
27. Smilkstein M.J., Knapp G.L., Kulig K.W., Rumack B.H. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. (1988); Analysis of the national multicenter study (1976 to 1985). N. Engl. J. Med. 319, 1557-1562.
28. Prescott L.F. (1983); Paracetamol overdosage. Pharmacological considerations and clinical management. Drugs. 25, 290-314.